PDS Biotechnology (PDSB) Prices 6M Share Common Offering at $2.75/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
PDS Biotechnology (PDSB) Tops Q2 EPS by 4c
August 13, 2020 6:02 AM EDTPDS Biotechnology (NASDAQ: PDSB) reported Q2 EPS of ($0.19), $0.04 better than the analyst estimate of ($0.23).
Second Quarter 2020 and Recent Business Highlights
Announced publication of PDS0101 triple combination preclinical study by the National Cancer Institute;Initiated Phase 2 clinical trial of PDS0101 triple combination, led by the National Cancer Institute, for the treatment of advanced human papillomavirus (HPV)-associated cancers;Announced Phase 2 trial to evaluate PDS0101 in combination with standard of care for treatment of locally advanced cervical cancer at The University of Texas MD Anderson Cancer Center;Launched novel PDS Biotech-owned vaccine... MorePDS Biotechnology (PDSB) Announces Proposed Public Offering of Common Stock
August 10, 2020 4:38 PM EDTPDS Biotechnology Corporation (PDS Biotech or the Company) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune® T-cell activating technology, today announced that it intends to offer and sell shares of its common stock in an... More
